Physician profile
Michael S Rafii
NPI 1598875775
$111,981.87
in general payments reported to CMS, 2019-2025
8 companies · $61K in 2025
The $61K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2022: $2,648 · 2023: $48K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Travel and Lodging: $23K · Food and Beverage: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $51,266.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,100.00 |
| Travel and Lodging | $22,921.05 |
| Food and Beverage | $800.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $47,434.24 | 2023 | Adlarity, Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34,408.85 | 2025 | |
| Ionis Pharmaceuticals, INC. | $25,920.00 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $2,000.00 | 2022 | |
| Sumitomo Pharma Co., LTD. | $1,050.00 | 2023 | |
| Alkermes, INC. | $485.00 | 2022 | |
| Eisai INC. | $409.63 | 2019-2022 | |
| Otsuka Pharmaceutical Co., LTD. | $274.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rafii listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.